Suppr超能文献

暴发性心肌炎与 COVID-19 疫苗接种有关。

Fulminant Myocarditis Temporally Associated with COVID-19 Vaccination.

机构信息

De Gasperis Cardio Center, ASST Grande Ospedale Metropolitano Niguarda, Transplant Center, Milan, Italy.

Department of Health Sciences, University of Milano-Bicocca, Monza, Italy.

出版信息

Curr Cardiol Rep. 2024 Mar;26(3):97-112. doi: 10.1007/s11886-024-02021-w. Epub 2024 Feb 7.

Abstract

PURPOSE OF REVIEW

Coronavirus disease-2019 (COVID-19) vaccines have been related to rare cases of acute myocarditis, occurring between 1 in 10,000 and 1 in 100,000 individuals, approximately. Incidence of COVID-19 vaccine-associated myocarditis varies with age, sex, and type of vaccine. Although most patients with acute myocarditis temporally associated with COVID-19 vaccines have an uneventful course, a small subpopulation presents with cardiogenic shock (termed fulminant myocarditis [FM]). This review explored the prevalence, clinical presentation, management, and prognosis of COVID-19 vaccine-associated acute myocarditis, specifically focusing on FM and comparing patients with fulminant versus non-fulminant myocarditis.

RECENT FINDINGS

Cases of FM represent about 2-4% (0 to 7.5%) of COVID-19 vaccine-associated acute myocarditis cases, and mortality is around 1%, ranging between 0 and 4.4%. First, we identified 40 cases of FM up to February 2023 with sufficient granular data from case reports and case series of COVID-19 vaccine-associated acute myocarditis that occurred within 30 days from the last vaccine injection. This population was compared with 294 cases of non-fulminant acute myocarditis identified in the literature during a similar time. Patients with FM were older (48 vs. 27 years), had a larger proportion of women (58% vs. 9%), and mainly occurred after the first shot compared with non-fulminant cases (58% vs. 16%). The reported mortality was 27% (11 out of 40), in line with non-vaccine-associated fulminant myocarditis. These data were in agreement with 36 cases of FM from a large Korean registry. Herein, we reviewed the clinical features, imaging results, and histological findings of COVID-19 vaccine-associated fulminant myocarditis. In conclusion, COVID-19 vaccine-associated FM differs from non-fulminant forms, suggesting potential specific mechanisms in these rare and severe forms. Mortality in vaccine-associated FM remains high, in line with other forms of FM.

摘要

目的综述

新冠肺炎(COVID-19)疫苗与罕见的急性心肌炎相关,其发生率约为每 10000 至 100000 人中 1 例。COVID-19 疫苗相关心肌炎的发生率与年龄、性别和疫苗类型有关。尽管大多数与 COVID-19 疫苗相关的急性心肌炎患者病程平稳,但一小部分患者会出现心源性休克(称为暴发性心肌炎[FM])。本综述探讨了 COVID-19 疫苗相关急性心肌炎的流行情况、临床表现、治疗和预后,特别关注 FM,并比较了 FM 患者与非 FM 患者。

最新发现

FM 病例占 COVID-19 疫苗相关急性心肌炎的 2-4%(0 至 7.5%),死亡率约为 1%,范围在 0 至 4.4%之间。首先,我们从 COVID-19 疫苗接种后 30 天内发生的与急性心肌炎相关的病例报告和病例系列中确定了 40 例 FM 病例,这些病例具有足够的详细数据。将该人群与文献中在同一时间段内确定的 294 例非 FM 性急性心肌炎病例进行比较。FM 患者年龄较大(48 岁比 27 岁),女性比例较高(58%比 9%),且主要发生在首次注射后。报告的死亡率为 27%(40 例中有 11 例),与非疫苗相关性 FM 相符。这些数据与韩国一个大型注册研究中的 36 例 FM 相符。在此,我们回顾了 COVID-19 疫苗相关 FM 的临床特征、影像学结果和组织学发现。总之,COVID-19 疫苗相关 FM 与非 FM 形式不同,提示这些罕见且严重形式可能存在特定机制。疫苗相关 FM 的死亡率仍然很高,与其他形式的 FM 相符。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验